Medicare Part D

Last updated
Centers for Medicare and Medicaid Services logo Centers for Medicare and Medicaid Services logo.svg
Centers for Medicare and Medicaid Services logo

Medicare Part D, also called the Medicare prescription drug benefit, is an optional United States federal-government program to help Medicare beneficiaries pay for self-administered prescription drugs. [1] Part D was enacted as part of the Medicare Modernization Act of 2003 and went into effect on January 1, 2006. Under the program, drug benefits are provided by private insurance plans that receive premiums from both enrollees and the government. Part D plans typically pay most of the cost for prescriptions filled by their enrollees. [2] However, plans are later reimbursed for much of this cost through rebates paid by manufacturers and pharmacies. [3]

Contents

Part D enrollees cover a portion of their own drug expenses by paying cost-sharing. The amount of cost-sharing an enrollee pays depends on the retail cost of the filled drug, the rules of their plan, and whether they are eligible for additional Federal income-based subsidies. Prior to 2010, enrollees were required to pay 100% of their retail drug costs during the coverage gap phase, commonly referred to as the "doughnut hole.” Subsequent legislation, including the Affordable Care Act, “closed” the doughnut hole from the perspective of beneficiaries, largely through the creation of a manufacturer discount program. [4]

In 2019, about three-quarters of Medicare enrollees obtained drug coverage through Part D. [5] Program expenditures were $102 billion, which accounted for 12% of Medicare spending. [6] Through the Part D program, Medicare finances more than one-third of retail prescription drug spending in the United States. [7]

Program specifics

Eligibility and enrollment

To enroll in Part D, Medicare beneficiaries must also be enrolled in either Part A or Part B. Beneficiaries can participate in Part D through a stand-alone prescription drug plan or through a Medicare Advantage plan that includes prescription drug benefits. [8] Beneficiaries can enroll directly through the plan's sponsor or through an intermediary. Medicare beneficiaries who delay enrollment into Part D may be required to pay a late-enrollment penalty. [9] In 2019, 47 million beneficiaries were enrolled in Part D, which represents three-quarters of Medicare beneficiaries. [5]

Plans offered

Part D benefits are provided through private plans approved by the federal government. The number of offered plans varies geographically, but a typical enrollee will have dozens of options to choose from. [10] Although plans are restricted by numerous program requirements, plans vary in many ways. Among other factors, enrollees often compare premiums, covered drugs, and cost-sharing policies when selecting a plan.

Medicare offers an interactive online tool [11] that allows for comparison of coverage and costs for all plans in a geographic area. The tool lets users input their own list of medications and then calculates personalized projections of the enrollee's annual costs under each plan option. Plans are required to submit biweekly data updates that Medicare uses to keep this tool updated throughout the year.

Costs to beneficiaries

Beneficiary cost sharing

A simplified version of the Medicare Part D standard benefit in 2021 Part D Standard Benefit 2021.png
A simplified version of the Medicare Part D standard benefit in 2021

Part D includes a statutorily defined "standard benefit" that is updated on an annual basis. All Part D sponsors must offer a plan that follows the standard benefit. The standard benefit is defined in terms of the benefit structure and without mandating the drugs that must be covered. For example, under the 2020 standard benefit, beneficiaries first pay a 100% coinsurance amount up to a $435 deductible. [12] Second, beneficiaries pay a 25% coinsurance amount up to an Out-of-Pocket Threshold of $6,350. In the final benefit phase, beneficiaries pay the greater of a 5% coinsurance amount or a nominal co-payment amount. These three benefit phases are referred to as the Deductible, Initial Coverage Limit, and the Catastrophic phase.

The "Out-of-Pocket Threshold" is not a cap on out-of-pocket spending, as beneficiaries continue to accrue cost-sharing expenses in the Catastrophic phase. In 2020, beneficiaries would typically reach this threshold as their retail drug spending approached $10,000. When patients enter the Catastrophic phase, the amount they have paid in cost-sharing is typically much less than the Out-of-Pocket Threshold. This is because the standard benefit requires plans to include additional amounts, such as manufacturer discounts, when determining if the Out-of-Pocket Threshold has been met.

Part D sponsors may also offer plans that differ from the standard benefit, provided that these alternative benefit structures do not result in higher average cost-sharing. In practice, most enrollees do not elect for standard benefit plans, instead opting for plans without deductibles and with tiered drug co-payments rather than coinsurance. [8] Enrollees must pay an additional premium amount to be enrolled in a plan with cost-sharing that is lower than the standard benefit, and this additional amount is not Federally-subsidized.

Prior to 2010, the standard benefit included a Coverage Gap phase in which, after accruing significant spending, relatively-high cost enrollees were required to pay a 100% coinsurance amount until they entered the Catastrophic phase. This Coverage Gap phase is commonly referred to as "the Donut Hole." Beginning with the Affordable Care Act, cost-sharing in the Coverage Gap phase has been gradually reduced. Despite no longer triggering elevated cost-sharing, the Coverage Gap phase continues to exist for other administrative purposes.

Beneficiary premiums

In 2020, the average monthly Part D premium across all plans was $27. [13] Premiums for stand-alone PDPs are 3 times higher than premiums for MA-PDs, as Medicare Advantage plans often use federal rebates to reduce premiums for drug coverage. [14] Enrollees typically pay their premiums directly to plans, though they may opt to have their premiums automatically deducted from their Social Security checks.

Plans offer competitive premiums to attract enrollees. Premiums must cover the cost of both plan liability and the reinsurance subsidy. From 2017 to 2020, despite rising per capita drug spending, premiums decreased by 16%. [13] [15] Plans have been able to lower premiums by negotiating larger rebates from manufacturers and pharmacies. Between 2017 and 2020, the percentage of drug costs rebated back to plans increased from 22% to 28%. [16] In addition, the standard benefit was changed in 2019 to increase mandatory manufacturer discounts in the Coverage Gap. [17] [18]

Part D practices community rating, with all enrollees in a plan being assigned the same premium. Enrollees do pay more in premiums if they enroll in higher-than-average-cost plans or in plans that offer enhanced benefits. Like in Part B, higher-income enrollees are required to pay an additional premium amount. Low-income enrollees may have their premium reduced or eliminated if they qualify for the low-income premium subsidy.

For 2022, costs for stand-alone Part D plans in the 10 major U.S. markets ranged from a low of $6.90-per-month (Dallas and Houston) to as much as $160.20-per-month (San Francisco). A study by the American Association for Medicare Supplement Insurance reported the lowest and highest 2022 Medicare Plan D costs [19] for the top-10 markets.

Retiree drug subsidy (RDS)

Retiree Drug Subsidy (RDS) is a program that provides financial assistance to employers who offer prescription drug coverage to their retirees. The subsidy is a feature of Medicare Part D, designed to help retirees access affordable prescription medications. [20]

Low-income subsidies

Beneficiaries with income below 150% of the poverty line are eligible for the low-income subsidy, which helps pay for premiums and cost-sharing. Depending on income-level and assets, some beneficiaries qualify for the full low-income subsidy, while others are eligible for a partial subsidy. All low-income subsidy enrollees still pay small copayment amounts.

Low-income enrollees tend to have more chronic conditions than other enrollees. [21] Low-income subsidy enrollees represent about one-quarter of enrollment, [22] but about half of the program's retail drug spending. [2] Nearly 30% of Federal spending on Part D goes towards paying for the low-income subsidy. [23]

In addition to receiving premium and cost-sharing subsidies, certain program rules apply differently for low-income subsidy enrollees. Beneficiaries of the low-income subsidy are exempt from the Coverage Gap Manufacturer Discount Program. Low-income subsidy enrollees are also allowed to change plans more frequently than other enrollees. [24]

Excluded drugs

While Centers for Medicare & Medicaid Services (CMS) does not have an established formulary, Part D drug coverage excludes drugs not approved by the Food and Drug Administration, drugs not available by prescription for purchase in the United States, and drugs for which payments would be available under Part B. [25]

Part D coverage excludes drugs or classes of drugs that may be excluded from Medicaid coverage. These may include:

While these drugs are excluded from basic Part D coverage, drug plans can include them as a supplemental benefit, provided they otherwise meet the definition of a Part D drug. However plans that cover excluded drugs are not allowed to pass on those costs to Medicare, and plans are required to repay CMS if they are found to have billed Medicare in these cases. [26]

Plan formularies

Part D plans are not required to pay for all covered Part D drugs. [27] They establish their own formularies, or list of covered drugs for which they will make payment, as long as the formulary and benefit structure are not found by CMS to discourage enrollment by certain Medicare beneficiaries. Part D plans that follow the formulary classes and categories established by the United States Pharmacopoeia will pass the first discrimination test. Plans can change the drugs on their formulary during the course of the year with 60 days' notice to affected parties.

The primary differences between the formularies of different Part D plans relate to the coverage of brand-name drugs. Typically, each Plan's formulary is organized into tiers, and each tier is associated with a set co-pay amount. Most formularies have between 3 and 5 tiers. The lower the tier, the lower the co-pay. For example, Tier 1 might include all of the Plan's preferred generic drugs, and each drug within this tier might have a co-pay of $5 to $10 per prescription. Tier 2 might include the Plan's preferred brand drugs with a co-pay of $40 to $50, while Tier 3 may be reserved for non-preferred brand drugs which are covered by the plan at a higher co-pay, perhaps $70 to $100. Tiers 4 and higher typically contain specialty drugs, which have the highest co-pays because they are generally more expensive. By 2011 in the United States a growing number of Medicare Part D health insurance plans had added the specialty tier. [28] :1

History

The enactment of Medicare Part D immediately changed how prescription drug spending was financed in the United States. United States Per Capita Prescription Drug Expenditures, 1960-2019.png
The enactment of Medicare Part D immediately changed how prescription drug spending was financed in the United States.

Upon enactment in 1965, Medicare included coverage for physician-administered drugs, but not self-administered prescription drugs. While some earlier drafts of the Medicare legislation included an outpatient drug benefit, those provisions were dropped due to budgetary concerns. [29] In response to criticism regarding this omission, President Lyndon Johnson ordered the formation of the Task Force on Prescription Drugs. [30] The Task Force conducted a comprehensive review of the American prescription drug market and reported that many elderly Americans struggled to afford their medications. [31]

Despite the findings and recommendations of the Task Force, initial efforts to create a Medicare outpatient drug benefit were unsuccessful. In 1988, the Medicare Catastrophic Coverage Act temporarily expanded program benefits to include self-administered drugs. [32] However, this legislation was repealed just one year later, partially due to concerns regarding premium increases. The 1993 Clinton Health Reform Plan also included an outpatient drug benefit, but that reform effort ultimately failed due to a lack of public support. [33]

In the decades following Medicare's passage, prescription drug spending grew and became increasingly financed through third-party payment. Following an era of modest growth, per capita drug spending began growing rapidly in the 1980s. [34] This growth was partially spurred by the launch of many billion dollar “blockbuster drugs” like Lipitor, Celebrex, and Zoloft. [35] At the time of Medicare's passage, more than 90% of drug spending was paid out-of-pocket. [34] Over the following 35-years, third-party payment for prescription drugs became increasingly common. By the end of the century, less than one-third of drug spending was paid out-of-pocket. Despite the absence of a Medicare drug benefit, about 70% of Medicare enrollees obtained drug coverage through other means, often through an employer or Medicaid. [36]

Medicare began offering subsidized outpatient drug coverage in the mid-2000s. In the 2000 presidential election, both the Democratic and Republican candidates campaigned on the promise of using the projected federal budget surplus to fund a new Medicare drug entitlement program. [37] Following his electoral victory, President George W. Bush promoted a general vision of using private health plans to provide drug coverage to Medicare beneficiaries. [30] Rather than demand that the plan be budget neutral, President Bush supported up to $400 billion in new spending for the program. In 2003, President Bush signed the Medicare Modernization Act, which authorized the creation of the Medicare Part D program. The program was implemented in 2006.

To keep the plan's cost projections below the $400 billion constraint set by leadership, policymakers devised the infamous “donut hole.” After exceeding a modest deductible, beneficiaries would pay 25% cost-sharing for covered drugs. [30] However, once their spending reached an “initial coverage limit,” originally set at $2,250, their cost-sharing would return to 100% of the drug's cost. This loss in coverage would continue until the patient surpassed an out-of-pocket threshold Beneficiaries were often confused by this complicated design, [38] and research consistently found that this coverage gap reduced medication adherence. [39] [40] [41] The Affordable Care Act and subsequent legislation phased-out the coverage gap from the perspective of beneficiaries. As of 2020, beneficiary cost-sharing on covered drugs never exceeds 25% of the drug's cost after an enrollee meets their deductible. [42]

Program costs

In 2019, total drug spending for Medicare Part D beneficiaries was about $180 billion. [43] One-third of this amount, about $120 billion, was paid by prescription drug plans. This plan liability amount was partially offset by about $50 billion in discounts, mostly in the form of manufacturer and pharmacy rebates. [16] This implied a net plan liability (i.e. net of discounts) of roughly $70 billion. To finance this cost, plans received roughly $50 billion in federal reinsurance subsidies, $10 billion in federal direct subsidies, and $10 billion in enrollee premiums. [23]

In addition to the $60 billion paid in federal insurance subsidies, the federal government also paid about $30 billion in cost-sharing subsidies for low-income enrollees. [23] The federal government also collected roughly 20 billion in offsetting receipts. These offsets included both state payments made on behalf of Medicare beneficiaries who also qualify for full Medicaid benefits and additional premiums paid by high-income enrollees. After accounting for these offsets, the net federal cost of Part D was about $70 billion. [44]

Implementation issues

Impact on beneficiaries

A 2008 study found that the percentage of Medicare beneficiaries who reported forgoing medications due to cost dropped with Part D, from 15.2% in 2004 and 14.1% in 2005 to 11.5% in 2006. The percentage who reported skipping other basic necessities to pay for drugs also dropped, from 10.6% in 2004 and 11.1% in 2005 to 7.6% in 2006. The very sickest beneficiaries reported no reduction, but fewer reported forgoing other necessities to pay for medicine. [46] [47]

A parallel study found that Part D beneficiaries skip doses or switch to cheaper drugs and that many do not understand the program. [46] Another study found that Part D resulted in modest increases in average drug utilization and decreases in average out-of-pocket expenditures. [48] Further studies by the same group of researchers found that the net impact among beneficiaries was a decrease in the use of generic drugs. [49]

A further study concludes that although a substantial reduction in out-of-pocket costs and a moderate increase in utilization among Medicare beneficiaries during the first year after Part D, there was no evidence of improvement in emergency department use, hospitalizations, or preference-based health utility for those eligible for Part D during its first year of implementation. [50] It was also found that there were no significant changes in trends in the dual eligibles' out-of-pocket expenditures, total monthly expenditures, pill-days, or total number of prescriptions due to Part D. [51]

A 2020 study found that Medicare Part D led to a sharp reduction in the number of people over the age of 65 who worked full-time. The authors say that this is evidence that before the change, people avoided retiring in order to maintain employer-based health insurance. [52] [53]

Criticisms

The federal government is not permitted to negotiate Part D drug prices with drug companies, as federal agencies do in other programs. Numerous critics view this as a mismanagement of taxpayer funds, whereas proponents contend that allowing price negotiation might inhibit innovation by reducing profits for pharmaceutical companies. [54] The Department of Veterans Affairs, which is allowed to negotiate drug prices and establish a formulary, has been estimated to pay between 40% [55] and 58% [56] less for drugs, on average, than Part D. On the other hand, the VA only covers about half the brands that a typical Part D plan covers.

Part of the issue is that Medicare does not pay for Part D drugs, and so has no actual leverage. Part D drug providers are using the private insurer leverage, which is generally a larger block of consumers than the 40 million or so actually using Medicare parts A and B for medical care.

Although generic versions of [frequently prescribed to the elderly] drugs are now available, plans offered by three of the five [exemplar Medicare Part D] insurers currently exclude some or all of these drugs from their formularies. ... Further, prices for the generic versions are not substantially lower than their brand-name equivalents. The lowest price for simvastatin (generic Zocor) 20 mg is 706 percent more expensive than the VA price for brand-name Zocor. The lowest price for sertraline HCl (generic Zoloft) is 47 percent more expensive than the VA price for brand-name Zoloft."

Families USA 2007 "No Bargain: Medicare Drug Plans Deliver High Prices"

Estimating how much money could be saved if Medicare had been allowed to negotiate drug prices, economist Dean Baker gives a "most conservative high-cost scenario" of $332 billion between 2006 and 2013 (approximately $50 billion a year). Economist Joseph Stiglitz in his book entitled The Price of Inequality estimated a "middle-cost scenario" of $563 billion in savings "for the same budget window". [57] :48

Former Congressman Billy Tauzin, R–La., who steered the bill through the House, retired soon after and took a $2 million a year job as president of Pharmaceutical Research and Manufacturers of America (PhRMA), the main industry lobbying group. Medicare boss Thomas Scully, who threatened to fire Medicare Chief Actuary Richard Foster if he reported how much the bill would actually cost, was negotiating for a new job as a pharmaceutical lobbyist as the bill was working through Congress. [58] [59] 14 congressional aides quit their jobs to work for related lobbies immediately after the bill's passage. [60]

In response, free-market think tank Manhattan Institute issued a report by professor Frank Lichtenberg that said the VA National Formulary excludes many new drugs. Only 38% of drugs approved in the 1990s and 19% of the drugs approved since 2000 were on the formulary.[ citation needed ]

In 2012, the plan required Medicare beneficiaries whose total drug costs reach $2,930 to pay 100% of prescription costs until $4,700 is spent out of pocket. (The actual threshold amounts change year-to-year and plan-by-plan, and many plans offered limited coverage during this phase.) While this coverage gap does not affect the majority of program participants, about 25% of beneficiaries enrolled in standard plans find themselves in this gap. [61]

As a candidate, Barack Obama proposed "closing the 'doughnut hole'" and subsequently proposed a plan to reduce costs for recipients from 100% to 50% of these expenses. [62] The cost of the plan would be borne by drug manufacturers for name-brand drugs and by the government for generics. [62]

See also

Notes

  1. Kirchhoff, Suzanne M. (August 13, 2018). Medicare Part D Prescription Drug Benefit (PDF). Washington, DC: Congressional Research Service. Retrieved 29 August 2018.
  2. 1 2 A Data Book: Health Care Spending and the Medicare Program (PDF). Medicare Payment Advisory Commission. 2020. p. 168.
  3. Report to the Congress: Medicare Payment Policy (PDF). Medicare Payment Advisory Commission. 2020. p. 430.
  4. Closing the Coverage Gap — Medicare Prescription Drugs Are Becoming More Affordable (PDF). Centers for Medicare & Medicaid Services. 2014.
  5. 1 2 "Medicare—CBO's Baseline as of March 6, 2020" (PDF). CBO.gov. March 6, 2020. Retrieved July 9, 2021.
  6. Report to the Congress: Medicare Payment Policy (PDF). Medicare Payment Advisory Commission. 2021. p. 411.
  7. "Retail Sales for Prescription Drugs Filled at Pharmacies by Payer". Kaiser Family Foundation. 2020. Retrieved July 9, 2021.
  8. 1 2 "Medicare: A Primer," Archived 2010-06-12 at the Wayback Machine Kaiser Family Foundation, April 2010.
  9. "Part D late enrollment penalty". Centers for Medicare & Medicaid Services. Retrieved July 9, 2021.
  10. "An Overview of the Medicare Part D Prescription Drug Benefit". KFF. 2020-10-14. Retrieved 2021-07-09.
  11. "Medicare Plan Finder for Health, Prescription Drug and Medigap plans". www.medicare.gov. Retrieved 2018-03-29.
  12. "An Overview of the Medicare Part D Prescription Drug Benefit". 14 October 2020.
  13. 1 2 A Data Book: Health Care Spending and the Medicare Program(PDF) Archived 2021-07-11 at the Wayback Machine . Medicare Payment Advisory Commission. 2020. p. 155.
  14. Damico, Anthony (2020-10-29). "Medicare Part D: A First Look at Medicare Prescription Drug Plans in 2021". KFF. Retrieved 2021-07-12.
  15. "Medicare Part D Utilization: Average Annual Gross Drug Costs Per Part D Enrollee, by Type of Plan, Low Income Subsidy (LIS) Eligibility, and Brand/Generic Drug Classification" (PDF) Archived 2021-07-11 at the Wayback Machine . Centers for Medicare & Medicaid Services. Retrieved July 11, 2021.
  16. 1 2 2020 Medicare Trustees Report (PDF) Archived 2021-06-23 at the Wayback Machine . Centers for Medicare & Medicaid Services. 2020. p. 142.
  17. "2022 Medicare Drug Plan Prices - Best Part D Plan Prices Information". MedicareSupp.org. Retrieved 2021-10-25.
  18. Damico, Anthony (2021-06-08). "Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2021". KFF. Retrieved 2023-01-06.
  19. "American Association for Medicare Supplement Insurance". American Association for Medicare Supplement Insurance. October 2022.
  20. "Retiree Drug Subsidy (RDS)". www.rds.cms.hhs.gov. Retrieved 2023-10-05.
  21. Shoemaker, J. Samantha; Davidoff, Amy J.; Stuart, Bruce; Zuckerman, Ilene H.; Onukwugha, Eberechukwu; Powers, Christopher (2012). "Eligibility and Take-up of the Medicare Part D Low-Income Subsidy". Inquiry: The Journal of Health Care Organization, Provision, and Financing. 49 (3): 214–230. doi: 10.5034/inquiryjrnl_49.03.04 . PMID   23230703. S2CID   36621020.
  22. 2020 ANNUAL REPORT OF THE BOARDS OF TRUSTEES OF THE FEDERAL HOSPITAL INSURANCE AND FEDERAL SUPPLEMENTARY MEDICAL INSURANCE TRUST FUNDS (PDF). Centers for Medicare & Medicaid Services. 2020. p. 140.
  23. 1 2 3 2020 Medicare Trustees Report (PDF) Archived 2021-06-23 at the Wayback Machine . Centers for Medicare & Medicaid Services. 2020. p. 145.
  24. Medicare Part D Prescription Drug Benefit (PDF). Congressional Research Service. 2020. p. 4.
  25. "Relationship between Part B and Part D Coverage" (PDF). Archived from the original (PDF) on February 3, 2007.
  26. "Report on the Medicare Drug Discount Card Program Sponsor McKesson Health Solutions, A-06-06-00022" (PDF). Archived from the original (PDF) on 2011-07-17. Retrieved 2007-02-01.
  27. "Part D / Prescription Drug Benefits". Center for Medicare Advocacy. Retrieved 2023-01-06.
  28. Elias, Eve Carolyn (May 2011). Analysis of out-of-pocket expenditures of oral oncologics for Tennessee recipients of Medicare Part D (PDF). The University of Tennessee (Thesis). Master of Science. p. 54. Archived from the original (PDF) on 31 January 2016. Retrieved 17 October 2015.
  29. Marmor TR. The Politics of Medicare. 2nd ed. New York: Aldine de Gruyter; 2000.
  30. 1 2 3 Oliver, Thomas R; Lee, Philip R; Lipton, Helene L (June 2004). "A Political History of Medicare and Prescription Drug Coverage". The Milbank Quarterly. 82 (2): 283–354. doi:10.1111/j.0887-378X.2004.00311.x. ISSN   0887-378X. PMC   2690175 . PMID   15225331.
  31. Smith, M. C. (2001). Prescription drugs under Medicare: the legacy of the Task Force on Prescription Drugs. CRC Press.
  32. Rice, Thomas; Desmond, Katherine; Gabel, Jon (1990-01-01). "The Medicare Catastrophic Coverage Act: A Post-Mortem". Health Affairs. 9 (3): 75–87. doi: 10.1377/hlthaff.9.3.75 . ISSN   0278-2715. PMID   2227787.
  33. Skocpol, Theda (1995-01-01). "The Rise and Resounding Demise of the Clinton Plan". Health Affairs. 14 (1): 66–85. doi:10.1377/hlthaff.14.1.66. ISSN   0278-2715. PMID   7657229.
  34. 1 2 "National Health Expenditure Data | CMS". www.cms.gov. Retrieved 2021-07-19.
  35. Aitken, Murray; Berndt, Ernst R.; Cutler, David M. (January 2009). "Prescription drug spending trends in the United States: looking beyond the turning point". Health Affairs. 28 (1): w151–160. doi:10.1377/hlthaff.28.1.w151. ISSN   1544-5208. PMID   19088102.
  36. Kreling, D. H., Mott, D. A., & Wiederholt, J. B. (1997). Why are prescription drug costs rising. Hospital, 1994(1995), 1996.
  37. Blumenthal, D., & Morone, J. (2010). The heart of power: health and politics in the Oval Office. Univ of California Press.
  38. Polinski, Jennifer M.; Bhandari, Aman; Saya, Uzaib Y.; Schneeweiss, Sebastian; Shrank, William H. (2010-05-01). "Medicare beneficiaries' knowledge of and choices regarding Part D, 2005 – present". Journal of the American Geriatrics Society. 58 (5): 950–966. doi:10.1111/j.1532-5415.2010.02812.x. ISSN   0002-8614. PMC   2909383 . PMID   20406313.
  39. Gu, Q., Zeng, F., Patel, B. V., & Tripoli, L. C. (2010). Part D coverage gap and adherence to diabetes medications. The American journal of managed care, 16(12), 911-918.
  40. Li, Pengxiang; McElligott, Sean; Bergquist, Henry; Schwartz, J. Sanford; Doshi, Jalpa A. (2012-06-05). "Effect of the Medicare Part D Coverage Gap on Medication Use Among Patients With Hypertension and Hyperlipidemia". Annals of Internal Medicine. 156 (11): 776–784. doi:10.7326/0003-4819-156-11-201206050-00004. ISSN   0003-4819. PMID   22665815. S2CID   43798967.
  41. Zhang, Yuting; Baik, Seo Hyon; Lave, Judith R. (2013-06-01). "Effects of Medicare Part D Coverage Gap on Medication Adherence". The American Journal of Managed Care. 19 (6): e214–e224. ISSN   1088-0224. PMC   3711553 . PMID   23844750.
  42. Damico, Anthony (2018-08-21). "Closing the Medicare Part D Coverage Gap: Trends, Recent Changes, and What's Ahead". KFF. Retrieved 2021-07-19.
  43. A Data Book: Health Care Spending and the Medicare Program Archived 2021-08-10 at the Wayback Machine (PDF). Medicare Payment Advisory Commission. 2021. p. 171.
  44. 2020 Medicare Trustees Report (PDF) Archived 2021-09-13 at the Wayback Machine . Centers for Medicare & Medicaid Services. 2020. p. 98.
  45. The Institute of Medicine (2006). "Preventing Medication Errors". The National Academies Press. Retrieved 2006-07-21.[ permanent dead link ]
  46. 1 2 Gardner, Amanda (2008-04-22). "Medicare Prescription Drug Benefit Shows Mixed Results". The Washington Post . ISSN   0190-8286 . Retrieved 2023-01-06.
  47. Madden, Jeanne M.; Graves, Amy J.; Zhang, Fang; Adams, Alyce S.; Briesacher, Becky A.; Ross-Degnan, Dennis; Gurwitz, Jerry H.; Pierre-Jacques, Marsha; Safran, Dana Gelb; Adler, Gerald S.; Soumerai, Stephen B. (2008-04-23). "Cost-Related Medication Nonadherence and Spending on Basic Needs Following Implementation of Medicare Part D". JAMA. 299 (16): 1922–1928. doi:10.1001/jama.299.16.1922. ISSN   0098-7484. PMC   3781951 . PMID   18430911.
  48. Zhang, JX; Yin, W; Sun, SX; Alexander, GC (2008). "The impact of the Medicare Part D prescription benefit on generic drug use". J Gen Intern Med. 23 (10): 1673–8. doi:10.1007/s11606-008-0742-6. PMC   2533371 . PMID   18661190.
  49. Zhang, J; Yin, W; Sun, S; Alexander, GC (2008). "Impact of the Medicare Prescription Drug Benefit on the use of generic drugs". Journal of General Internal Medicine. 23 (10): 1673–1678. doi:10.1007/s11606-008-0742-6. PMC   2533371 . PMID   18661190.
  50. Liu, Frank Xiaoqing; Alexander, G. Caleb; Crawford, Stephanie Y.; Pickard, A. Simon; Hedeker, Donald; Walton, Surrey M. (August 2011). "The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility". Health Services Research. 46 (4): 1104–1123. doi:10.1111/j.1475-6773.2011.01273.x. PMC   3165180 . PMID   21609328.
  51. Basu, A; Yin W; Alexander GC (February 2010). "Impact of Medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures". Health Services Research. 1. 45 (1): 133–151. doi:10.1111/j.1475-6773.2009.01065.x. PMC   2813441 . PMID   20002765.
  52. Wettstein, Gal (2020). "Retirement Lock and Prescription Drug Insurance: Evidence from Medicare Part D". American Economic Journal: Economic Policy. 12 (1): 389–417. doi:10.1257/pol.20160560. ISSN   1945-7731. S2CID   84836195.
  53. "Will work for insurance". www.aeaweb.org. Retrieved 2020-03-16.
  54. Gailey, Adam; Lakdawalla, Darius; Sood, Neeraj (January 2010), Dor, Avi (ed.), "Patents, innovation, and the welfare effects of Medicare Part D", Advances in Health Economics and Health Services Research, 22, Emerald Group Publishing Limited: 317–344, doi:10.1108/s0731-2199(2010)0000022017, ISBN   978-1-84950-716-5, PMC   3988702 , PMID   20575239
  55. Austin, Frakt; Steven D. Pizer; Roger Feldman (May 2012). "Should Medicare Adopt the Veterans Health Administration Formulary?". Health Economics. 21 (5): 485–95. doi:10.1002/hec.1733. PMID   21506191. S2CID   41721060.
  56. "No Bargain: Medicare Drug Plans Deliver High Prices" (PDF). Families USA. 2007. Retrieved 2012-05-10.
  57. Stiglitz, Joseph E. (2012). The Price of Inequality . W.W. Norton & Company. p. 560. ISBN   978-0393345063.
  58. Under The Influence: 60 Minutes' Steve Kroft Reports On Drug Lobbyists' Role in Passing Bill That Keeps Drug Prices High . Lists Senators and Congress members who went on to high-paying jobs as pharmaceutical industry lobbyists after voting for Medicare Part D.
  59. The K Street Prescription Archived 2014-01-12 at the Wayback Machine , By Paul Krugman, New York Times, January 20, 2006.
  60. Singer, Michelle (March 29, 2007). "Under The Influence: 60 Minutes' Steve Kroft Reports On Drug Lobbyists' Role in Passing Bill That Keeps Drug Prices High". CBS News 60 Minutes.
  61. Zhang Y, Donohue JM, Newhouse JP, Lave JR. The effects of the coverage gap on drug spending: a closer look at Medicare Part D Archived 2015-10-15 at the Wayback Machine . Health Affairs. 2009 Mar-Apr;28(2):w317-25.
  62. 1 2 "Obama Unveils 'Doughnut Hole' Solution: People who fall in the Part D coverage gap would only pay half the cost of brand-name medications". AARP Bulletin Today. 2009-06-22.

Related Research Articles

<span class="mw-page-title-main">Medicaid</span> United States social health care program for families and individuals with limited resources

In the United States, Medicaid is a government program that provides health insurance for adults and children with limited income and resources. The program is partially funded and primarily managed by state governments, which also have wide latitude in determining eligibility and benefits, but the federal government sets baseline standards for state Medicaid programs and provides a significant portion of their funding.

<span class="mw-page-title-main">Medicare (United States)</span> US government health insurance program

Medicare is a federal health insurance program in the United States for people age 65 or older and younger people with disabilities, including those with end stage renal disease and amyotrophic lateral sclerosis. It was begun in 1965 under the Social Security Administration and is now administered by the Centers for Medicare and Medicaid Services (CMS).

Prescription drug list prices in the United States continually are among the highest in the world. The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015. One major reason for high prescription drug prices in the United States relative to other countries is the inability of government-granted monopolies in the American health care sector to use their bargaining power to negotiate lower prices, and the American payer ends up subsidizing the world's R&D spending on drugs.

<span class="mw-page-title-main">Medicare Prescription Drug, Improvement, and Modernization Act</span>

The Medicare Prescription Drug, Improvement, and Modernization Act, also called the Medicare Modernization Act or MMA, is a federal law of the United States, enacted in 2003. It produced the largest overhaul of Medicare in the public health program's 38-year history.

The Federal Employees Health Benefits (FEHB) Program is a system of "managed competition" through which employee health benefits are provided to civilian government employees and annuitants of the United States government. The government contributes 72% of the weighted average premium of all plans, not to exceed 75% of the premium for any one plan.

Dual-eligible beneficiaries refers to those qualifying for both Medicare and Medicaid benefits. In the United States, approximately 9.2 million people are eligible for "dual" status. Dual-eligibles make up 14% of Medicaid enrollment, yet they are responsible for approximately 36% of Medicaid expenditures. Similarly, duals total 20% of Medicare enrollment, and spend 31% of Medicare dollars. Dual-eligibles are often in poorer health and require more care compared with other Medicare and Medicaid beneficiaries.

Health care prices in the United States of America describe market and non-market factors that determine pricing, along with possible causes as to why prices are higher than in other countries.

The Balanced Budget Act of 1997 was an omnibus legislative package enacted by the United States Congress, using the budget reconciliation process, and designed to balance the federal budget by 2002. This act was enacted during Bill Clinton's second term as president.

In the United States, a pharmacy benefit manager (PBM) is a third-party administrator of prescription drug programs for commercial health plans, self-insured employer plans, Medicare Part D plans, the Federal Employees Health Benefits Program, and state government employee plans. PBMs operate inside of integrated healthcare systems, as part of retail pharmacies, and as part of insurance companies.

The Medicare Part D coverage gap was a period of consumer payments for prescription medication costs that lay between the initial coverage limit and the catastrophic coverage threshold when the consumer was a member of a Medicare Part D prescription-drug program administered by the United States federal government. The gap was reached after a shared insurer payment - consumer payment for all covered prescription drugs reached a government-set amount, and was left only after the consumer had paid full, unshared costs of an additional amount for the same prescriptions. Upon entering the gap, the prescription payments to date were re-set to $0 and continued until the maximum amount of the gap was reached or the then current annual period lapses. In calculating whether the maximum amount of gap had been reached, the "True-out-of-pocket" costs (TrOOP) were added together.

The Retiree Drug Subsidy Program is a program offered by the Centers for Medicare & Medicaid Services (CMS) to reimburse health plan sponsors for a portion of their eligible expenses for retiree prescription drug benefits. This enables Plan Sponsors to continue providing drug coverage to their Medicare-eligible retirees at a lower cost.

In the United States, health insurance helps pay for medical expenses through privately purchased insurance, social insurance, or a social welfare program funded by the government. Synonyms for this usage include "health coverage", "health care coverage", and "health benefits". In a more technical sense, the term "health insurance" is used to describe any form of insurance providing protection against the costs of medical services. This usage includes both private insurance programs and social insurance programs such as Medicare, which pools resources and spreads the financial risk associated with major medical expenses across the entire population to protect everyone, as well as social welfare programs like Medicaid and the Children's Health Insurance Program, which both provide assistance to people who cannot afford health coverage.


Medicare Advantage is a type of health plan offered by Medicare-approved private companies that must follow rules set by Medicare. Most Medicare Advantage Plans include drug coverage. Under Part C, Medicare pays a sponsor a fixed payment. The sponsor then pays for the health care expenses of enrollees. Sponsors are allowed to vary the benefits from those provided by Medicare's Parts A and B as long as they provide the actuarial equivalent of those programs. The sponsors vary from primarily integrated health delivery systems to unions to other types of non profit charities to insurance companies. The largest sponsor is a hybrid: the non-profit interest group AARP using UnitedHealth.

Medication costs, also known as drug costs are a common health care cost for many people and health care systems. Prescription costs are the costs to the end consumer. Medication costs are influenced by multiple factors such as patents, stakeholder influence, and marketing expenses. A number of countries including Canada, parts of Europe, and Brazil use external reference pricing as a means to compare drug prices and to determine a base price for a particular medication. Other countries use pharmacoeconomics, which looks at the cost/benefit of a product in terms of quality of life, alternative treatments, and cost reduction or avoidance in other parts of the health care system. Structures like the UK's National Institute for Health and Clinical Excellence and to a lesser extent Canada's Common Drug Review evaluate products in this way.

Healthcare rationing in the United States exists in various forms. Access to private health insurance is rationed on price and ability to pay. Those unable to afford a health insurance policy are unable to acquire a private plan except by employer-provided and other job-attached coverage, and insurance companies sometimes pre-screen applicants for pre-existing medical conditions. Applicants with such conditions may be declined cover or pay higher premiums and/or have extra conditions imposed such as a waiting period.

<span class="mw-page-title-main">The Path to Prosperity</span> U.S. budget proposal of the Republican Party

The Path to Prosperity: Restoring America's Promise was the Republican Party's budget proposal for the federal government of the United States in the fiscal year 2012. It was succeeded in March 2012 by "The Path to Prosperity: A Blueprint for American Renewal", the Republican budget proposal for 2013. Representative Paul Ryan, Chairman of the House Budget Committee, played a prominent public role in drafting and promoting both The Path to Prosperity proposals, and they are therefore often referred to as the Ryan budget, Ryan plan or Ryan proposal.

Health care finance in the United States discusses how Americans obtain and pay for their healthcare, and why U.S. healthcare costs are the highest in the world based on various measures.

Value-based insurance design is a demand-side approach to health policy reform. V-BID generally refers to health insurers' efforts to structure enrollee cost-sharing and other health plan design elements to encourage enrollees to consume high-value clinical services – those that have the greatest potential to positively impact enrollee health. V-BID also discourages the use of low-value clinical services – when benefits do not justify the cost. V-BID aims to increase health care quality and decrease costs by using financial incentives to promote cost efficient health care services and consumer choices. V-BID health insurance plans are designed with the tenets of "clinical nuance" in mind. These tenets recognize that medical services differ in the amount of health produced, and the clinical benefit derived from a specific service depends on the consumer using it, as well as when and where the service is provided.

The Patient Protection and Affordable Care Act, often shortened to the Affordable Care Act (ACA) or nicknamed Obamacare, is a United States federal statute enacted by the 111th United States Congress and signed into law by President Barack Obama on March 23, 2010. Together with the Health Care and Education Reconciliation Act of 2010 amendment, it represents the U.S. healthcare system's most significant regulatory overhaul and expansion of coverage since the passage of Medicare and Medicaid in 1965. Once the law was signed, provisions began taking effect, in a process that continued for years. Some provisions never took effect, while others were deferred for various periods.

<span class="mw-page-title-main">Elijah Cummings Lower Drug Costs Now Act</span> Proposed legislation

The Elijah Cummings Lower Drug Costs Now Act is proposed legislation in the 117th United States Congress. The bill is designed to lower prescription drug costs in the United States. Notably, the law gives the federal government the power to negotiate prescription drug prices. The legislation takes the name of late Maryland Representative Elijah Cummings.

References

Further reading

2019

2007

2006

2004

Government resources
Other resources